Research Article
Chimerism in Myeloid Malignancies following Stem Cell Transplantation Using FluBu4 with and without Busulfan Pharmacokinetics versus BuCy
Table 1
Summary of patient characteristics by treatment group.
| | | FluBu4 with PK | FluBu4 without PK | BuCy
| P value | | | | | (% or range) | (% or range) | (% or range) |
| | Gender | M 14 (67%) | M 24 (70%) | M 12 (52%) | .349 | | F 7 (33%) | F 10 (30%) | F 11 (48%) | | Median age at time of SCT | 59 (41–70) | 63 (48–72) | 45 (22–63) | <.001 | | Disease | | | | .006 | | Acute myeloid leukemia | 15 (71%) | 15 (44%) | 19 (82%) | | | MPN/MDS | 6 (29%) | 19 (56%) | 4 (18%) | | | Median blasts in bone marrow at time of SCT | 4% (1–40%) | 4% (1–20%) | 4% (1–90%) | .910 | | Cytogenetic risk | | | | .521 | | High | 14 (67%) | 17 (50%) | 14 (61%) | | | Intermediate | 6 (29%) | 16 (47%) | 9 (39%) | | | Low | 1 (4%) | 1 (3%) | 0 (0%) | | | Disease risk index | | | | .372 | | Intermediate | 9 (43%) | 16 (47%) | 7 (30%) | | | High | 5 (24%) | 13 (38%) | 9 (39%) | | | Very high | 7 (33%) | 5 (15%) | 7 (30%) | | | Antithymocyte globulin use | 12 (57%) | 21 (62%) | 10 (44%) | .38 | | CD34 dose × 106 | 3.9 ± 1.5 | 4.1 ± 1.3 | 4.4 ± 2 | .534 | | Donor type | | | | .401 | | Matched related donor | 9 (43%) | 13 (38%) | 12 (52%) | | | Matched unrelated donor | 7 (33%) | 15 (44%) | 10 (43%) | | | Mismatched unrelated donor | 5 (24%) | 6 (18%) | 1 (5%) | |
|
|
Bu, busulfan; Cy, cyclophosphamide; F, female; Flu, fludarabine; M, male; MDS, myelodysplastic syndrome; MPN; myeloproliferative neoplasm; SCT, stem cell transplant.
|
